Impact of Histology and PD-L1 Status on Immune Checkpoint Inhibitors in the Treatment of Non–Small Cell Lung Cancer a Systemic Review and Meta-analysis
Khalil Choucair(The Barbara Ann Karmanos Cancer Institute), Hirva Mamdani(Wayne State University), Dipesh Uprety(The Barbara Ann Karmanos Cancer Institute), Seongho Kim(Wayne State University), Hyejeong Jang(The Barbara Ann Karmanos Cancer Institute), Shadia I. Jalal(Indiana University Health), Tarik Hadid(Wayne State University)
Cited by 0
Related Papers
Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies
|Journal of Thoracic Oncology|2019|437
Immunotherapy in Lung Cancer: Current Landscape and Future Directions
|Frontiers in Immunology|2022|373
Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158.
|Journal of Clinical Oncology|2018|208
Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline
|Journal of Clinical Oncology|2022|125
Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline
|Journal of Clinical Oncology|2022|116